Tag - MDNA

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...